229 results on '"Penaloza-MacMaster, Pablo"'
Search Results
2. Therapeutic role of interferon-γ in experimental autoimmune encephalomyelitis is mediated through a tolerogenic subset of splenic CD11b+ myeloid cells
3. Pre-existing immunity modulates responses to mRNA boosters
4. An attenuated lymphocytic choriomeningitis virus vector enhances tumor control in mice partly via IFN-I
5. Time-dependent enhancement of mRNA vaccines by 4-1BB costimulation
6. Bat scan could insure against future pandemics
7. Improved control of SARS-CoV-2 by treatment with a nucleocapsid-specific monoclonal antibody
8. Therapeutic role of interferon-γ in experimental autoimmune encephalomyelitis is mediated through a tolerogenic subset of splenic CD11b+ myeloid cells.
9. Replication-attenuated r3LCMV vectors potentiate tumor control via IFN-I
10. Improved control of SARS-CoV-2 infection with nucleocapsid-specific antibodies
11. Corrigendum: Neuro-PASC is characterized by enhanced CD4+ and diminished CD8+ T cell responses to SARSCoV-2 Nucleocapsid protein
12. Cross-protective immunity following coronavirus vaccination and coronavirus infection
13. Neuro-PASC is characterized by enhanced CD4+ and diminished CD8+ T cell responses to SARS-CoV-2 Nucleocapsid protein
14. Pre-existing immunity modulates responses to mRNA boosters
15. 4-1BB costimulation following mRNA vaccination improves CD8 T cell responses
16. Development of novel replication-defective lymphocytic choriomeningitis virus vectors expressing SIV antigens
17. A single-cell atlas reveals shared and distinct immune responses and metabolic profiles in SARS-CoV-2 and HIV-1 infections
18. Respiratory viruses: New frontiers—a Keystone Symposia report
19. Mild SARS-CoV-2 Infection Promotes Autoantibody Production in Long COVID Patients Despite Vaccination
20. Inhibitory receptor expression on memory CD8 T cells following Ad vector immunization
21. Vaccine-elicited CD4 T cells induce immunopathology after chronic LCMV infection
22. Adoptive B cell therapy for chronic viral infection
23. Regulation of CD4 T cells and their effects on immunopathological inflammation following viral infection
24. Pre-existing immunity modulates responses to mRNA boosters
25. Nucleocapsid-specific humoral responses improve the control of SARS-CoV-2
26. A single-cell atlas reveals shared and distinct immune responses and metabolism during SARS-CoV-2 and HIV-1 infections
27. Altered T Cell Responses to SARS-CoV-2 Correlate with Neurologic Symptom Severity in Long COVID
28. Fractionating a COVID-19 Ad5-vectored vaccine improves virus-specific immunity
29. Tolerance Induced by Antigen-Loaded PLG Nanoparticles Affects the Phenotype and Trafficking of Transgenic CD4+ and CD8+ T Cells
30. A Multifunctional Neutralizing Antibody‐Conjugated Nanoparticle Inhibits and Inactivates SARS‐CoV‐2
31. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys
32. RAPID ESTABLISHMENT OF THE VIRAL RESERVOIR PRIOR TO SYSTEMIC VIREMIA FOLLOWING MUCOSAL SIV INFECTION OF RHESUS MONKEYS: O1.07
33. Combining spike- and nucleocapsid-based vaccines improves distal control of SARS-CoV-2
34. T cell responses to SARS-CoV-2 in people with and without neurologic symptoms of long COVID
35. T CELL VACCINES: Vaccine-elicited CD4 T cells induce immunopathology after chronic LCMV infection
36. Adoptive B cell therapy for chronic viral infection.
37. PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells
38. SARS coronavirus vaccines protect against different coronaviruses
39. Nanotraps for the containment and clearance of SARS-CoV-2
40. Blockade of IFN-I improves adaptive immune responses and immune coverage after vaccination
41. Reducing the priming dose of a SARS CoV-2 vaccine improves vaccine-elicited immunity
42. Adoptive B cell therapy improves viral control during a chronic viral infection.
43. Characterization of cross-reactive immunity following coronavirus vaccination or natural infection
44. A SARS CoV-2 nucleocapsid vaccine protects against distal viral dissemination
45. Limiting the priming dose of a SARS CoV-2 vaccine improves virus-specific immunity
46. Viral vaccines improve PD-1 therapy against cancer
47. Early type I IFN blockade improves the efficacy of viral vaccines
48. Targeting Scavenger Receptor Type B-1 (SR-B1) and Cholesterol Inhibits Entry of SARS-CoV-2 Pseudovirus in Cell Culture
49. A Neutralizing Antibody-Conjugated Photothermal Nanoparticle Captures and Inactivates SARS-CoV-2
50. A Multifunctional Neutralizing Antibody‐Conjugated Nanoparticle Inhibits and Inactivates SARS‐CoV‐2.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.